362 related articles for article (PubMed ID: 16749855)
1. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target.
Balakrishnan A; Polli JE
Mol Pharm; 2006; 3(3):223-30. PubMed ID: 16749855
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT).
Rais R; Fletcher S; Polli JE
J Pharm Sci; 2011 Mar; 100(3):1184-95. PubMed ID: 20848648
[TBL] [Abstract][Full Text] [Related]
3. Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation.
Balakrishnan A; Wring SA; Polli JE
Pharm Res; 2006 Jul; 23(7):1451-9. PubMed ID: 16783481
[TBL] [Abstract][Full Text] [Related]
4. The lipid flippase heterodimer ATP8B1-CDC50A is essential for surface expression of the apical sodium-dependent bile acid transporter (SLC10A2/ASBT) in intestinal Caco-2 cells.
van der Mark VA; de Waart DR; Ho-Mok KS; Tabbers MM; Voogt HW; Oude Elferink RP; Knisely AS; Paulusma CC
Biochim Biophys Acta; 2014 Dec; 1842(12 Pt A):2378-86. PubMed ID: 25239307
[TBL] [Abstract][Full Text] [Related]
5. Role of the intestinal bile acid transporters in bile acid and drug disposition.
Dawson PA
Handb Exp Pharmacol; 2011; (201):169-203. PubMed ID: 21103970
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups.
Kolhatkar V; Polli JE
Eur J Pharm Sci; 2012 May; 46(1-2):86-99. PubMed ID: 22387310
[TBL] [Abstract][Full Text] [Related]
7. Putative irreversible inhibitors of the human sodium-dependent bile acid transporter (hASBT; SLC10A2) support the role of transmembrane domain 7 in substrate binding/translocation.
González PM; Hussainzada N; Swaan PW; Mackerell AD; Polli JE
Pharm Res; 2012 Jul; 29(7):1821-31. PubMed ID: 22354836
[TBL] [Abstract][Full Text] [Related]
8. The SLC10 carrier family: transport functions and molecular structure.
Döring B; Lütteke T; Geyer J; Petzinger E
Curr Top Membr; 2012; 70():105-68. PubMed ID: 23177985
[TBL] [Abstract][Full Text] [Related]
9. Site-directed mutagenesis and use of bile acid-MTS conjugates to probe the role of cysteines in the human apical sodium-dependent bile acid transporter (SLC10A2).
Banerjee A; Ray A; Chang C; Swaan PW
Biochemistry; 2005 Jun; 44(24):8908-17. PubMed ID: 15952798
[TBL] [Abstract][Full Text] [Related]
10. Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter.
Balakrishnan A; Wring SA; Coop A; Polli JE
Mol Pharm; 2006; 3(3):282-92. PubMed ID: 16749860
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel nonsteroidal compounds as substrates or inhibitors of hASBT.
Kolhatkar V; Diao L; Acharya C; Mackerell AD; Polli JE
J Pharm Sci; 2012 Jan; 101(1):116-26. PubMed ID: 22109685
[TBL] [Abstract][Full Text] [Related]
12. An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT).
Xiao L; Pan G
Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):509-515. PubMed ID: 28336180
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids.
González PM; Lagos CF; Ward WC; Polli JE
Mol Pharm; 2014 Feb; 11(2):588-98. PubMed ID: 24328955
[TBL] [Abstract][Full Text] [Related]
14. Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges.
Li M; Wang Q; Li Y; Cao S; Zhang Y; Wang Z; Liu G; Li J; Gu B
Pharmacol Ther; 2020 Aug; 212():107539. PubMed ID: 32201314
[TBL] [Abstract][Full Text] [Related]
15. PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution.
Han X; Sun J; Wang Y; He Z
Curr Drug Metab; 2015; 16(1):71-83. PubMed ID: 25828592
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine Phosphorylation Regulates Plasma Membrane Expression and Stability of the Human Bile Acid Transporter ASBT (
Chothe PP; Czuba LC; Ayewoh EN; Swaan PW
Mol Pharm; 2019 Aug; 16(8):3569-3576. PubMed ID: 31194565
[TBL] [Abstract][Full Text] [Related]
17. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.
Anwer MS; Stieger B
Pflugers Arch; 2014 Jan; 466(1):77-89. PubMed ID: 24196564
[TBL] [Abstract][Full Text] [Related]
18. Increased acyclovir oral bioavailability via a bile acid conjugate.
Tolle-Sander S; Lentz KA; Maeda DY; Coop A; Polli JE
Mol Pharm; 2004 Jan; 1(1):40-8. PubMed ID: 15832499
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of genetic variants in the apical sodium-dependent bile acid transporter (ASBT; SLC10A2).
Ho RH; Leake BF; Urquhart BL; Gregor JC; Dawson PA; Kim RB
J Gastroenterol Hepatol; 2011 Dec; 26(12):1740-8. PubMed ID: 21649730
[TBL] [Abstract][Full Text] [Related]
20. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships.
Geyer J; Wilke T; Petzinger E
Naunyn Schmiedebergs Arch Pharmacol; 2006 Mar; 372(6):413-31. PubMed ID: 16541252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
